- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07694492
Feasibility of a Medical-Legal Partnership Model to Connect Coal Miners QuitAid
Determining the Feasibility of Utilizing a Medical-Legal Partnership Model to Reach Coal Miners Who Use Tobacco and Nicotine Products and Connect Them to a Pharmacy-based Cessation Program
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Background and rationale. Lung cancer rates are approximately 25% higher in Central Appalachia than in the rest of the U.S., and black-lung mortality has been markedly elevated in the region. Coal miners report the highest rates of cigarette smoking (about 23% vs. ~14% nationally) and smokeless tobacco use (about 23% vs. ~3% nationally) of any U.S. occupation, and TNP use magnifies the risk and severity of obstructive lung disease and lung cancer in this already high-risk group. National guidelines recommend that clinicians refer TNP users to cessation services via ask-advise-connect, but time constraints, limited provider buy-in, and patient factors limit adoption. In workers' compensation cases, claimants must prove their disease results from coal-dust exposure rather than TNP use, which creates both a health and a financial incentive for cessation and gives the miner-lawyer relationship unusual salience. This study leverages that relationship by having lawyers ask about TNP use (already routine at intake), advise quitting, and connect interested clients to a pharmacist-delivered cessation program (the novel component). QuitAid, previously developed and piloted by the study team, is a pharmacist-delivered MTM intervention designed to increase NRT adherence and promote cessation.
Aim 1 (implementation evaluation, lawyers). Guided by the Consolidated Framework for Implementation Research (CFIR), the team evaluates facilitators and barriers to adopting the ask-advise-connect model in approximately three black-lung law offices. Lawyers (up to 5 enrolled) complete baseline and follow-up surveys assessing self-efficacy, attitudes, and perceived facilitators/barriers, and participate in ~30-minute semi-structured telephone interviews (audio-recorded, analyzed thematically). Recruitment feasibility is measured by the proportion of coal miners referred per office and the number enrolled per month. Lawyers are study participants only, not investigators, and referral has no effect on a miner's legal case.
Aim 2 (randomized feasibility pilot, coal miners). Coal miners who use TNPs and have a current black-lung workers' compensation case with a participating law office are referred, screened, and consented by phone, complete a baseline assessment, and are then randomized 1:1 via computer-generated permuted-block randomization (generated in R, embedded in REDCap) to QuitAid (Yes vs. No). All participants receive 24 weeks of NRT beginning in Week 1 regardless of readiness to quit. Participants use of smoked TNPs (cigarettes, e-cigarettes, little cigars, cigarillos, cigars) receive the long-acting NRT patch; those using oral TNPs (smokeless tobacco, nicotine pouches) receive short-acting NRT gum; those using both receive the patch. Participants randomized to QuitAid who are ready to quit receive six telephonic pharmacist coaching sessions over 4 weeks; those not ready to quit receive up to three telephonic Pre-Quit Motivation Modules and may transition to QuitAid if they report readiness at any weekly check-in during Weeks 1-4. If readiness is not reported after four weekly check-ins, QuitAid ends. Follow-up assessments are conducted with all participants at 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks via secure REDCap links or telephone. Because this is a feasibility pilot, secondary clinical outcomes are analyzed descriptively and with logistic regression only to inform a future full-scale trial.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Dylan Allanson, MPH, RD
- Telefonnummer: 4342430424
- E-Mail: da4ac@virginia.edu
Studieren Sie die Kontaktsicherung
- Name: Ashley N DeMoss, MPH
- Telefonnummer: (304) 574-8073
- E-Mail: fzv3nn@virginia.edu
Studienorte
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22903
- University of Virginia
-
Unterermittler:
- Roger T Anderson, PhD
-
Kontakt:
- Ashley N DeMoss, MPH
- Telefonnummer: (304) 574-8073
- E-Mail: fzv3nn@virginia.edu
-
Hauptermittler:
- Melissa A Little, PhD, MPH
-
Hauptermittler:
- Drew Harris, MD
-
Unterermittler:
- Candace H Wood, PharmD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age ≥ 18 years
- Able to read, speak, and understand English
- A coal miner who uses tobacco and nicotine products, lives in the U.S., and has a current black-lung workers' compensation case with a participating law office
- Reports using tobacco and nicotine products daily for the past 6 months
- Willing and able to use NRT in the form of patch or gum
- Not pregnant or planning to become pregnant in the next 6 months
Exclusion Criteria:
- Medical contraindication to NRT (e.g., within the past 30 days: heart attack or stroke; within the past 6 months: serious or worsening angina, or very rapid or irregular heartbeat requiring medication)
- Pregnant or breastfeeding, or planning to become pregnant during the next 6 months
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: QuitAid + NRT
Participants receive the pharmacist-delivered QuitAid MTM program plus 24 weeks of NRT.
Those ready to quit receive six telephonic coaching sessions over 4 weeks; those not ready to quit receive up to three Pre-Quit Motivation Modules and may transition to QuitAid upon reporting readiness at a weekly check-in (Weeks 1-4).
|
Six telephonic pharmacist coaching sessions over 4 weeks focused on setting a quit date and quitting TNPs.
The first session (and subsequent proactive calls at ~days 2, 7, 14, 21, and 28) addresses negative beliefs about NRT, strengthens motivation and commitment to NRT use, monitors NRT use, provides feedback, and supports adherence.
Includes the Pre-Quit Motivation Modules (up to three telephonic sessions) for participants not yet ready to quit.
Andere Namen:
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
|
Aktiver Komparator: NRT Only
Participants receive 24 weeks of NRT beginning in Week 1 without the QuitAid MTM program.
All follow-up assessments are conducted regardless of condition.
|
24 weeks of NRT dispensed under a standing order and mailed to participants, with standard use guidelines.
Product is matched to TNP type: long-acting patch for smoked TNP users, short-acting gum for oral TNP users, patch for dual users.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Feasibility of Randomization
Zeitfenster: Through study recruitment (approximately 6 months)
|
Number of coal miners who need to be approached and screened in order to randomize 100 TNP users.
|
Through study recruitment (approximately 6 months)
|
|
Retention
Zeitfenster: 26 weeks
|
Proportion of randomized coal miners who complete the 26-week follow-up visit.
|
26 weeks
|
|
Fidelity of Implementation
Zeitfenster: Through the 4-week intervention period
|
Fidelity of QuitAid delivery, assessed as adherence to QuitAid, quality of program delivery, participant responsiveness, and program differentiation, captured via a session checklist and self-reported end-of-session reflections.
|
Through the 4-week intervention period
|
|
Dose of the Medication Therapy Management (MTM) Intervention
Zeitfenster: Through the 4-week intervention period
|
Number of MTM (QuitAid) sessions received per participant, documented in the REDCap database.
|
Through the 4-week intervention period
|
|
Dose of NRT
Zeitfenster: Baseline through 26 weeks
|
Reported proportion of provided NRT that was used by participants.
|
Baseline through 26 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Self-Reported Tobacco Abstinence
Zeitfenster: 1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
Self-reported abstinence, defined as no use of any tobacco or nicotine products within the past 7 days.
|
1, 2, 3, 4, 7, 11, 15, 19, and 26 weeks
|
|
Quit Attempts
Zeitfenster: Baseline through 26 weeks
|
Number of quit attempts since the previous contact, where a quit attempt is abstinence for ≥24 hours not due to involuntary or forced cessation (e.g., hospitalization).
|
Baseline through 26 weeks
|
|
Frequency of Urges to Use TNPs
Zeitfenster: Baseline through 26 weeks
|
Self-reported frequency of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
|
Adherence to Assigned Treatment(s)
Zeitfenster: Baseline through 26 weeks
|
Percentage of intervention sessions completed and percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Adherence to NRT
Zeitfenster: Baseline through 26 weeks
|
Adherence to NRT (patch or gum), measured as the percentage of provided NRT used.
|
Baseline through 26 weeks
|
|
Strength of urges to use TNPs
Zeitfenster: Baseline through 26 weeks
|
Self-reported strength of urges to use tobacco/nicotine products.
|
Baseline through 26 weeks
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Program satisfaction
Zeitfenster: 26 weeks
|
Participant-reported barriers to treatment utilization, satisfaction with treatment components, and suggestions for improvement, with items focused on perceived capacity and opportunity to engage with the interventions.
|
26 weeks
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Melissa A Little, PhD, MPH, University of Virginia
- Hauptermittler: Drew Harris, MD, University of Virginia
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Psychische Störungen
- Erkrankungen der Atemwege
- Lungenkrankheit
- Substanzbezogene Störungen
- Chemisch induzierte Störungen
- Lungenerkrankungen, Interstitial
- Lungenverletzung
- Pneumokoniose
- Verhalten
- Gesundheitsverhalten
- Tabakkonsumstörung
- Raucherentwöhnung
- Tabakkonsumentwöhnung
- Anthrakose
- Verwaltung des Gesundheitswesens
- Therapeutika
- Arzneimitteltherapie
- Gesundheitsdienste
- Belegschaft und Dienstleistungen für Gesundheitseinrichtungen
- Gesundheitsökonomie und Organisationen
- Patientenversorgung Management
- Finanzierung, organisiert
- Wirtschaft
- Pharmazeutische Dienstleistungen
- Medicare Teil D
- Versicherung, pharmazeutische Dienstleistungen
- Krankenversicherung
- Versicherung
- Medicare
- Nikotinersatztherapie
- Medikamentöse Therapiesteuerung
Andere Studien-ID-Nummern
- HSR 303071
- 5P30CA044579-30 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Tabakkonsumstörung
-
University of KonstanzAfrica Mental Health FoundationAbgeschlossenKhat-Use-StörungKenia
-
University of Massachusetts, WorcesterAgency for Healthcare Research and Quality (AHRQ); Omnicare Clinical Research; Qualidig...AbgeschlossenOff-Label-Use von atypischen AntipsychotikaVereinigte Staaten
-
University of North Carolina, Chapel HillRekrutierungOff-Label-Use von Medikamenten bei pädiatrischen PatientenVereinigte Staaten
-
University of KonstanzAfrica Mental Health FoundationAbgeschlossenPosttraumatische Belastungsstörung | Khat-Use-StörungKenia
Klinische Studien zur QuitAid (pharmacist-delivered MTM)
-
University of VirginiaAktiv, nicht rekrutierend
-
University of VirginiaRekrutierungRauchen | Raucherentwöhnung | Reduzierung des Rauchens | Rauchen, Tabak | Rauchen, Zigarette | Aufhören zu rauchenVereinigte Staaten